260 related articles for article (PubMed ID: 28874354)
21. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
22. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.
Xiao H; Peng Y; Hong Y; Huang L; Guo ZS; Bartlett DL; Fu N; Munn DH; Mellor A; He Y
J Immunol; 2013 Jun; 190(11):5866-73. PubMed ID: 23610140
[TBL] [Abstract][Full Text] [Related]
23. Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.
McNamara MJ; Hilgart-Martiszus I; Barragan Echenique DM; Linch SN; Kasiewicz MJ; Redmond WL
Cancer Immunol Res; 2016 Aug; 4(8):650-7. PubMed ID: 27262113
[TBL] [Abstract][Full Text] [Related]
24. Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis.
Shitaoka K; Hamana H; Kishi H; Hayakawa Y; Kobayashi E; Sukegawa K; Piao X; Lyu F; Nagata T; Sugiyama D; Nishikawa H; Tanemura A; Katayama I; Murahashi M; Takamatsu Y; Tani K; Ozawa T; Muraguchi A
Cancer Immunol Res; 2018 Apr; 6(4):378-388. PubMed ID: 29475880
[TBL] [Abstract][Full Text] [Related]
25. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
[TBL] [Abstract][Full Text] [Related]
26. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.
Park BV; Freeman ZT; Ghasemzadeh A; Chattergoon MA; Rutebemberwa A; Steigner J; Winter ME; Huynh TV; Sebald SM; Lee SJ; Pan F; Pardoll DM; Cox AL
Cancer Discov; 2016 Dec; 6(12):1366-1381. PubMed ID: 27683557
[TBL] [Abstract][Full Text] [Related]
27. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
[TBL] [Abstract][Full Text] [Related]
28. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
[TBL] [Abstract][Full Text] [Related]
30. CD8
Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
[TBL] [Abstract][Full Text] [Related]
31. Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8
Hurst KE; Lawrence KA; Essman MT; Walton ZJ; Leddy LR; Thaxton JE
Cancer Immunol Res; 2019 Mar; 7(3):476-486. PubMed ID: 30659052
[TBL] [Abstract][Full Text] [Related]
32. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8
Buchan SL; Fallatah M; Thirdborough SM; Taraban VY; Rogel A; Thomas LJ; Penfold CA; He LZ; Curran MA; Keler T; Al-Shamkhani A
Clin Cancer Res; 2018 May; 24(10):2383-2394. PubMed ID: 29514845
[No Abstract] [Full Text] [Related]
33. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.
Martinez-Usatorre A; Sempere LF; Carmona SJ; Carretero-Iglesia L; Monnot G; Speiser DE; Rufer N; Donda A; Zehn D; Jandus C; Romero P
Cancer Immunol Res; 2019 Jun; 7(6):1013-1024. PubMed ID: 31043416
[TBL] [Abstract][Full Text] [Related]
34. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Webb JR; Milne K; Nelson BH
Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
[TBL] [Abstract][Full Text] [Related]
35. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
Hall M; Liu H; Malafa M; Centeno B; Hodul PJ; Pimiento J; Pilon-Thomas S; Sarnaik AA
J Immunother Cancer; 2016; 4():61. PubMed ID: 27777771
[TBL] [Abstract][Full Text] [Related]
36. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
[TBL] [Abstract][Full Text] [Related]
37. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
38. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
39. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
Seo H; Kim BS; Bae EA; Min BS; Han YD; Shin SJ; Kang CY
Cancer Immunol Res; 2018 Jun; 6(6):685-695. PubMed ID: 29615398
[TBL] [Abstract][Full Text] [Related]
40. TCR Repertoire Analysis Reveals Mobilization of Novel CD8
Aoki H; Ueha S; Shichino S; Ogiwara H; Hashimoto SI; Kakimi K; Ito S; Matsushima K
Front Immunol; 2018; 9():3185. PubMed ID: 30733724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]